A Reliance Agreement, also referred to as an IRB Authorization Agreement, allows the IRB of one institution to rely on the IRB of another institution for review of human subjects research. The scope of the reliance agreement may be limited to a specific protocol or to any protocol agreed upon by both parties on a case-by-case basis.
The University of Mississippi Medical Center has a reliance agreement with the WIRB-Copernicus Group to allow for review by WIRB IRB, CGIRB and its partner IRBs for industry-sponsored, industry-initiated studies where the sponsor has selected WIRB or one of its partners as the reviewing IRB. Registering to use WIRB is easy.
Log on to https://connexus.wirb.com.
The University of Mississippi Medical Center has a reliance agreement with Schulman for industry-sponsored, industry-initiated studies where the sponsor has selected Schulman as the reviewing IRB.
The University of Mississippi Medical Center has a reliance agreement with the National Cancer Institute Central IRB (NCI CIRB) to rely on the NCI CIRB review for certain cooperative group oncology trials.
* Studies that require Radiation Safety (RSC), Biosafety and Embryonic Stem Cell (ESCRO) review will continue to submit to UMMC's RSC, Biosafety, and ESCRO. The committee determination letters will be submitted with the abbreviated application.
All amendments (including personnel changes), continuing reviews and final reports must be submitted first to the external IRB for approval. Once approved by the external IRB, an abbreviated application for the approved amendment, continuing review, and final report can be submitted to the Human Research Office through REDCap. UMMC’s IRB requires that a final report application be submitted in REDCap for record keeping purposes even if the reviewing, external IRB does not accept final reports.